Pharmacological Evaluation Institute of Japan (PEIJ), General Incorporated Association
"make a future together"
Pharmacological Evaluation Institute of Japan (PEIJ) is a non-profit pharmacology research institute. We are working with the activities globally for improvement in the reliability of the evaluation method of toxicity / safety and efficacy used in the case of drug development and chemical safety as an "ADAPTER". We are also working for STEAM education for all in the SDGs.
The E14/S7B IWG, ICH, will build on work done by the former E14/S7B Discussion Group (DG) which discussed the advances in science and methods related to the clinical assessment of QT prolongation and worked on the Comprehensive in vitro Proarrhythmia Assessment (CiPA) initiative.
PEIJ makes a poster presentation, "New Approach for Neuropharmacology Profile: In-Situ Real-Time Neuropharmacology Monitoring by Imaging Technique Using the Molecularly Imprinted Polymers (MIPs)", at Safety Pharmacology Society 2018 Annual Meeting.
Results from a Blinded CiPA Pailot Study
Daniel Millard, Qianyu Dang, Hong Shi, Xiaou Zhang, Chris Strock, Udo Kraushaar, Haoyu Zeng, Paul Levesque, Hua-Rong Lu, Jean-Michel Guillon, Joseph C Wu, Yingxin Li, Greg Luerman, Blake Anson, Liang Guo, Mike Clements, Yama A Abassi, James Ross, Jennifer Pierson, Gary Gintant. Cross-Site Reliability of Human Induced Pluripotent Stem-Cell Derived Cardiomyocyte Based Safety Assays using Microelectrode Arrays: Results from a Blinded CiPA Pilot Study, Toxicological Sciences. 2018
PEIJ has an advanced science program for younger generation. We started a "PEIJ Youth Science Lab" and junior/senior high school students are joining us as PEIJ Junior Researchers. They are enjoying their own research activity including thesis reading/writing, discussion with richly experienced researchers, awareness survey, cell culture, etc. We encourage PEIJ Junior Researchers to think for themselves.
World Topic: CiPA in Hindsight Roundtable Discussion
This roundtable discussion is presented by Ncardia and HESI and describes the current and evolving roles of human-induced pluripotent stem cell-derived cardiomyocytes and drug safety.